Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist
Contact+90 (538) 677 60 18

New Pre-Post Surgery Options for Bladder Cancer: Durvalumab and Enfortumab Received FDA Approval

New Pre-Post Surgery Options for Bladder Cancer: Durvalumab and Enfortumab Received FDA Approval
In this article

A Second Option for Patients Who Cannot Receive Cisplatin: Durvalumab with Enfortumab Vedotin Before and After Bladder Cancer Surgery

On 13 November 2026, the US Food and Drug Administration (FDA) approved durvalumab (Imfinzi) together with enfortumab vedotin (Padcev) as treatment before surgery (neoadjuvant) for muscle-invasive bladder cancer, followed by durvalumab alone after surgery (adjuvant). The approval covers adults who are ineligible for cisplatin-containing chemotherapy or who decline this chemotherapy. In the VOLGA trial, compared with surgery alone, this treatment reduced the risk of the disease coming back or progressing by 49% and the risk of loss of life by 42%. About a year earlier, the combination of pembrolizumab and enfortumab vedotin had been approved for this patient group. In this article, I explain the firsts this new approval brings, the VOLGA results, an indirect comparison of the two options and the situation in Türkiye. I covered the earlier approval in my article on pembrolizumab and enfortumab vedotin.

49%reduction in the risk of an event (HR 0.51); 64% versus 45% at 2 years
42%reduction in the risk of loss of life (HR 0.58); 78% versus 69% alive at 2 years
40% / 8%no tumour remaining at surgery (pathological complete response)
695patients enrolled in VOLGA who could not receive or did not want cisplatin (3 arms)
Quick Answer · Physician's Summary
  • What was approved? Three cycles of treatment before surgery with durvalumab 1,500 mg and enfortumab vedotin 1.25 mg/kg (days 1 and 8), radical cystectomy, then durvalumab alone for up to 9 cycles. For muscle-invasive bladder cancer in patients who are cisplatin-ineligible or who decline cisplatin.
  • Evidence: Phase 3 VOLGA (695 patients, 3 arms). Compared with surgery alone, event-free survival HR 0.51; 64% versus 45% at 2 years. Overall survival HR 0.58; 78% versus 69% at 2 years. Pathological complete response 40% versus 8%.
  • What is new? The first perioperative approval of a PD-L1 inhibitor with an antibody–drug conjugate. Enfortumab vedotin is not given after surgery; only durvalumab continues. Patients who decline cisplatin are explicitly included in the approval text.
  • Where does it stand? Alongside pembrolizumab and enfortumab vedotin, it is the second perioperative option shown to prolong survival in patients who cannot receive cisplatin. The two treatments have not been compared directly. This use is not licensed in Türkiye.

Why does this matter?

Muscle-invasive bladder cancer is the stage at which the tumour has grown into the muscle layer of the bladder wall. The standard treatment is removal of the bladder (radical cystectomy). In about half of the patients treated with surgery alone, the disease comes back within a few years. For many years, giving cisplatin-containing chemotherapy before surgery was the only proven way to reduce this risk (bladder cancer guide).

However, bladder cancer is mostly seen at an older age. About half of patients cannot receive cisplatin because of kidney function, hearing loss, nerve damage, heart failure or general condition. Some others do not want chemotherapy. Until recently, only surgery could be offered to these patients. The approval within the last year of two separate treatments shown to prolong survival in this group is an important change in bladder cancer treatment (kidney failure, immunotherapy before surgery).

A first? The firsts in this approval and a short history
  • First joint approval of durvalumab and enfortumab vedotin: The use of a PD-L1 inhibitor with an antibody–drug conjugate around surgery has been approved for the first time.
  • Patients "declining cisplatin" in the approval text: The pembrolizumab and enfortumab vedotin approval covered "cisplatin-ineligible" patients. The VOLGA approval explicitly includes patients who do not want chemotherapy as well.
  • Two perioperative approvals for durvalumab in bladder cancer: Durvalumab has become the first PD-L1 inhibitor to receive two separate perioperative approvals in bladder cancer: with chemotherapy in cisplatin-eligible patients (NIAGARA, 2025) and with enfortumab vedotin in ineligible patients (VOLGA, 2026).
  • No antibody–drug conjugate after surgery: Enfortumab vedotin is given only before surgery, for 3 cycles. In the pembrolizumab regimen, by contrast, enfortumab vedotin is also given after surgery.
2019
First approval of enfortumab vedotin
The nectin-4-targeting antibody–drug conjugate was approved in advanced bladder cancer after chemotherapy and immunotherapy.
2023
First line in advanced disease
Enfortumab vedotin and pembrolizumab were approved as first treatment of advanced bladder cancer (EV-302).
March 2025
NIAGARA
Durvalumab was approved with gemcitabine-cisplatin before and after surgery in cisplatin-eligible patients.
2025-2026
Pembrolizumab and enfortumab vedotin
Perioperative approval in patients who cannot receive cisplatin in November 2025 (KEYNOTE-905) and in cisplatin-eligible patients in July 2026 (KEYNOTE-B15).
13 November 2026
VOLGA
Durvalumab and enfortumab vedotin were approved in patients who cannot receive or do not want cisplatin. The application was reviewed under Project Orbis together with the medicines agencies of six countries.

Who is a cisplatin-ineligible patient?

A cisplatin-ineligible patient is one with reduced kidney function (creatinine clearance below 60 ml/min), poor general condition, hearing loss or grade 2 or higher nerve damage, or advanced heart failure. In patients who meet any one of these criteria, the harm of cisplatin may outweigh its benefit.

This definition was set by expert consensus and is also used in clinical trials. In addition to these patients, VOLGA also enrolled patients who were eligible for cisplatin but did not want chemotherapy. According to the information available before the approval, the benefit was similar in the two groups: HR 0.53 in cisplatin-ineligible patients and HR 0.49 in those declining cisplatin.

How do the two drugs work?

Enfortumab vedotin (Padcev) is an antibody–drug conjugate that binds to nectin-4, a protein found in abundance on the surface of most bladder cancer cells. Once inside the cell, it releases MMAE, a potent drug that stops cell division (antibody–drug conjugates). Durvalumab (Imfinzi), in turn, is an immunotherapy drug that blocks PD-L1, the protein tumour cells use to put the brakes on the immune system. The tumour cells broken down by enfortumab vedotin stimulate the immune system, and durvalumab removes the brake standing in the way of this response. The two effects are thought to reinforce each other (immunotherapy approvals in bladder cancer).

Figure 1 · How the two drugs work together

Antibody–drug conjugate and immunotherapy

Enfortumab vedotinbinds to nectin-4,enters the cell andreleases MMAE Durvalumablifts the PD-L1brake; T cellsrecognise the tumour Tumour cell cannot divide and breaks downreleased tumour fragments stimulate the immune system A stronger response togetherno tumour left at surgery: rose from 8% to 40%
How to read it: Enfortumab vedotin binds to nectin-4 on the tumour cell, enters the cell and releases MMAE, a drug that stops cell division. Durvalumab lifts the PD-L1 brake, allowing T cells to recognise the tumour. Fragments released from the broken-down tumour cells stimulate the immune system. In VOLGA, this combination raised the rate of no tumour remaining at surgery from 8% to 40%.

How was the VOLGA trial conducted?

VOLGA is an open-label, randomised phase 3 trial in which 695 patients with muscle-invasive bladder cancer who were candidates for cystectomy and were cisplatin-ineligible or declined cisplatin were divided into three arms. In the first arm (233 patients), durvalumab and enfortumab vedotin were given before surgery and durvalumab alone after surgery. In the second arm (229 patients), only radical cystectomy was performed; follow-up after surgery or post-operative treatment approved in that country was allowed. In the third arm (233 patients), tremelimumab, another immunotherapy drug, was added to these two drugs. The primary endpoint of the trial was event-free survival (EFS) by independent, blinded review. The results were presented at the ESMO Congress in October 2026.

Figure 2 · The approved treatment schedule

3 cycles before surgery, surgery, then up to 9 cycles

Cisplatin-ineligible or declining cisplatinadults with MIBC who are candidates for cystectomy Before surgery: 3 cycles (about 9 weeks)durvalumab 1,500 mg every 3 weeks+ enfortumab vedotin 1.25 mg/kg, days 1 and 8 Radical cystectomyremoval of the bladder and lymph nodes After surgery: durvalumab alone1,500 mg every 4 weeks, up to 9 cycles (about 9 months)
How to read it: In a patient with muscle-invasive bladder cancer who is a candidate for cystectomy and is cisplatin-ineligible or declines cisplatin, 3 cycles (about 9 weeks) of durvalumab 1,500 mg every three weeks and enfortumab vedotin 1.25 mg/kg on days 1 and 8 of each cycle are given before surgery. The bladder and lymph nodes are then removed (radical cystectomy). After surgery, durvalumab alone continues at 1,500 mg every four weeks for up to 9 cycles (about 9 months). In patients weighing less than 30 kg, the durvalumab dose is 20 mg/kg.

What was found?

At a median follow-up of about 23 months, the risk of disease progression, recurrence or loss of life fell by 49% in those receiving durvalumab and enfortumab vedotin compared with surgery alone (HR 0.51; 95% CI 0.38-0.67). The proportion of patients alive without an event after two years was 64% versus 45%; in other words, 19 more out of every 100 patients completed two years without an event. Median event-free survival was 12.1 months in the surgery-alone arm and has not yet been reached in the drug arm.

In overall survival, the risk of loss of life fell by 42% (HR 0.58; 95% CI 0.40-0.83). The proportion of patients alive after two years was 78% versus 69%; a difference of 9 people per 100 patients. The rate of no tumour remaining at surgery (pathological complete response) was 40% versus 8%. The benefit was similar in those with high (HR 0.58) and low (HR 0.46) tumour PD-L1 levels. In an exploratory analysis, tumour DNA in the blood disappeared with pre-operative treatment in 60% of the patients in whom it was detected (ctDNA tests).

VOLGA: durvalumab and enfortumab vedotin versus surgery alone

Durvalumab + enfortumab vedotin (coloured) and radical cystectomy alone (grey), %.

Alive without an event at 1 year
73%
Surgery alone
50%
Alive without an event at 2 years
64%
Surgery alone
45%
Alive at 2 years
78%
Surgery alone
69%
No tumour remaining at surgery (pCR)
40%
Surgery alone
8%

Event-free survival HR 0.51 (95% CI 0.38-0.67); the median has not yet been reached in the drug arm and was 12.1 months in the surgery-alone arm. Overall survival HR 0.58 (0.40-0.83); the median was not reached in either arm. Median follow-up about 23 months.

Did adding tremelimumab help?

Event-free survival was also significantly prolonged in the triplet arm (HR 0.61), but the difference in overall survival was not significant at the interim analysis (HR 0.77; 95% CI 0.54-1.07). Serious treatment-related side effects were more common in this arm (42% versus 30%), and 5 treatment-related losses of life were seen (1 in the doublet arm). For this reason, the FDA approved only the doublet combination. It is an instructive result showing that more drugs do not always bring more benefit.

Could surgery be performed?

The main concern with treatment before surgery is that side effects may delay or prevent the operation. In VOLGA, the radical cystectomy rate was higher in the drug arm (85% versus 78%). Surgery was delayed in 4% versus 0.4%; in the drug arm, surgery was cancelled in only 0.9% of patients.

Side effects

In those receiving durvalumab and enfortumab vedotin, grade 3–4 side effects from all causes occurred in 64% versus 44%; the rate of treatment-related grade 3–4 side effects was 30%. One of the drugs was stopped because of side effects in 21% of patients. The most common side effects were itching, urinary tract infection, anaemia, diarrhoea, constipation, loss of appetite, rash, nausea, fatigue, hair loss and taste changes.

Side effects in VOLGA

Durvalumab + enfortumab vedotin arm (n = 228), %.

Grade 3–4 side effects (all causes)
64%
In the surgery-alone arm
44%
Treatment-related grade 3–4 side effects
30%
Skin reactions
49%
Itching
44%
Immune-mediated adverse events
33%
Peripheral neuropathy
18%
Stopping one of the drugs
21%

Treatment-related loss of life occurred in 1 patient (0.4%). Surgery was delayed in 4% versus 0.4%; surgery was cancelled in 0.9%. Grade 3–4 immune-mediated adverse events occurred in 11%.

  • Skin reactions (49%): This is the most important side effect of enfortumab vedotin. The US product information carries a boxed warning for rare but serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis). Mouth sores, widespread rash or blistering of the skin should be reported immediately (skin side effects of immunotherapy).
  • Peripheral neuropathy (18%): Numbness and tingling in the hands and feet; mostly mild.
  • Raised blood sugar: Can occur with enfortumab vedotin; close monitoring is needed in people with diabetes (cancer and diabetes).
  • Immune-mediated adverse events (33%; severe in 11%): Inflammation of the thyroid, liver, lungs, bowel and kidneys due to durvalumab. In VOLGA, there was no loss of life from this cause (immunotherapy side effects, endocrine side effects, kidney side effects).
  • Urinary tract infection (36%): Common with bladder cancer and around the time of surgery; seeking care early for fever or burning is important (signs of infection in cancer).

Indirect comparison with pembrolizumab and enfortumab vedotin

There are now two FDA-approved perioperative options for patients who cannot receive cisplatin. The two treatments have not been compared in the same trial; the table below is intended only to give a rough idea.

Feature KEYNOTE-905 (pembrolizumab + EV) VOLGA (durvalumab + EV)
FDA approval 21 November 2025 13 November 2026
Patient group (approval text) Cisplatin-ineligible Cisplatin-ineligible or declining cisplatin
Number of patients 344 (two arms) 695 (three arms)
Before surgery 3 cycles of pembrolizumab + EV 3 cycles of durvalumab + EV
After surgery 6 cycles of pembrolizumab + EV, then pembrolizumab (about 42 weeks) Durvalumab alone, up to 9 cycles
Event-free survival (HR) 0.40 0.51
Overall survival (HR) 0.50 0.58
Pathological complete response 57.1% versus 8.6% 40% versus 8%
Median event-free survival in the control arm 15.7 months 12.1 months

At first glance, the numbers appear to favour the pembrolizumab combination. However, this difference must be interpreted with caution. The trials differ in the patients enrolled (VOLGA also included those declining chemotherapy), follow-up times, whether post-operative treatment was allowed in the control arm and the way pathological response was assessed. On the other hand, in the VOLGA regimen enfortumab vedotin is not given after surgery; this shortens exposure to skin and nerve side effects. Which treatment to choose should be decided according to the patient's risk of side effects, the length of treatment and access. I described the pitfalls of placing the results of different trials side by side in my article on reading research results correctly.

Perioperative immunotherapy combinations: hazard ratios

HR for event-free (EFS) and overall survival (OS); below 1 means benefit. KEYNOTE-905 and B15: pembrolizumab + EV; VOLGA: durvalumab + EV; NIAGARA: durvalumab + chemotherapy.

KEYNOTE-905 · EFS
0.40
KEYNOTE-905 · OS
0.50
VOLGA · EFS
0.51
VOLGA · OS
0.58
KEYNOTE-B15 · EFS
0.53
KEYNOTE-B15 · OS
0.65
NIAGARA · EFS
0.68
NIAGARA · OS
0.75

Coloured rows are trials versus surgery alone in patients who cannot receive cisplatin; grey rows are trials versus gemcitabine-cisplatin in cisplatin-eligible patients. Hazard ratios are naturally higher in trials whose control arm is chemotherapy, so the grey and coloured rows are not interchangeable. Comparisons across different studies are indirect; patient populations, prior treatments and follow-up times differ.

The current landscape in muscle-invasive bladder cancer

Two years ago, the only proven drug treatment that could be used around surgery in muscle-invasive bladder cancer was cisplatin-based chemotherapy. Today there are four separate FDA-approved perioperative options containing immunotherapy. In cisplatin-eligible patients: durvalumab with gemcitabine-cisplatin (NIAGARA) and pembrolizumab with enfortumab vedotin (KEYNOTE-B15); in cisplatin-ineligible patients: pembrolizumab with enfortumab vedotin (KEYNOTE-905) and durvalumab with enfortumab vedotin (VOLGA). In selected patients who do not want surgery or are not suitable for it, bladder-sparing chemoradiotherapy remains an important alternative (bladder-sparing treatment).

Figure 3 · Perioperative options

FDA approvals, November 2026

Treatment options before and after surgeryFDA approvals, November 2026 Cisplatin-eligibledurvalumab +gemcitabine-cisplatinNIAGARA · 2025 Cisplatin-eligiblepembrolizumab +enfortumab vedotinKEYNOTE-B15 · 2026 Cisplatin-ineligiblepembrolizumab +enfortumab vedotinKEYNOTE-905 · 2025 Cisplatin-ineligibledurvalumab +enfortumab vedotinVOLGA · November 2026 Bladder-sparing treatment in selected patientstumour removal + chemoradiotherapy; if surgery declined
How to read it: There are two options for cisplatin-eligible patients: durvalumab with gemcitabine-cisplatin (NIAGARA, 2025) and pembrolizumab with enfortumab vedotin (KEYNOTE-B15, 2026). There are also two options for cisplatin-ineligible patients: pembrolizumab with enfortumab vedotin (KEYNOTE-905, 2025) and the newly approved durvalumab with enfortumab vedotin (VOLGA, November 2026). In selected patients who do not want surgery, bladder-sparing treatment with removal of the tumour and chemoradiotherapy is an option.

The role of immunotherapy in bladder cancer is expanding rapidly, from disease that has not invaded the muscle to advanced disease (pembrolizumab in BCG-unresponsive bladder cancer). Durvalumab is also approved for use before and after surgery in lung cancer (chemo-immunotherapy before surgery in lung cancer).

FDA approvals of the agents

Drug Selected FDA approvals
Durvalumab (Imfinzi) Stage 3 non-small cell lung cancer (2018); extensive-stage SCLC (2020); biliary tract cancer (2022); liver cancer, with tremelimumab (2022); endometrial cancer (2024); lung cancer before and after surgery (2024); limited-stage SCLC (2024); muscle-invasive bladder cancer, with chemotherapy (2025) and with enfortumab vedotin (2026)
Enfortumab vedotin (Padcev) Advanced bladder cancer after prior treatment (2019, 2021); first line in advanced disease with pembrolizumab (2023); perioperative in muscle-invasive bladder cancer with pembrolizumab (2025, 2026); perioperative with durvalumab (2026)
Pembrolizumab (Keytruda) Approved in many cancer types; in bladder cancer, BCG-unresponsive disease, advanced disease and perioperative treatment (my Keytruda article)

The situation in Türkiye

Durvalumab (Imfinzi) and enfortumab vedotin (Padcev) are licensed medicines in our country. However, I believe this new perioperative use is not included in the Turkish licence; at the time of writing, I could not verify any licence update. Therefore, off-label use approval from the Ministry of Health is required for its use, and SGK reimbursement is not expected. I explained the indications for which durvalumab is reimbursed by SGK in my article on SGK conditions for immunotherapy. For the general framework on licensed but non-reimbursed medicines, see my articles on licensed but non-reimbursed cancer medicines and SGK reimbursement conditions, and for how new FDA-approved medicines reach our country, see the access map.

Questions you can ask your doctor

  • Can I receive cisplatin; if not, why not?
  • How much benefit would drug treatment before surgery bring me?
  • Which is more suitable for me: the pembrolizumab or the durvalumab combination?
  • What should I watch out for regarding skin, nerve and blood sugar side effects?
  • How can this treatment be obtained in Türkiye; what would off-label approval and the cost involve?
  • Is a bladder-sparing treatment option suitable for me?
Common myths
  • "A patient who cannot receive cisplatin can only have surgery." Not any more. There are now two perioperative treatments shown to prolong survival in these patients.
  • "The durvalumab combination is weaker than the pembrolizumab combination." This is not yet known. The two treatments have not been compared directly; the trials include different patient groups and follow-up times.
  • "Treatment before surgery delays the operation." In VOLGA, the surgery rate was higher in the drug arm; delay occurred in 4% of patients.
  • "Adding tremelimumab would be better." No. In the triplet arm, the survival difference was not significant and side effects were more frequent.
  • "If there is a pathological complete response, the cancer is completely gone." It is a good sign, but it does not reduce the chance of recurrence to zero; post-operative treatment and follow-up continue.

Frequently Asked Questions

For which patients were durvalumab and enfortumab vedotin approved?
On 13 November 2026, the FDA approved this combination as treatment before surgery for adults with muscle-invasive bladder cancer who are candidates for radical cystectomy and who are ineligible for cisplatin-based chemotherapy or do not want this chemotherapy. After surgery, durvalumab alone continues for up to 9 cycles.
How effective was the treatment in the VOLGA trial?
Compared with surgery alone, the risk of disease progression or recurrence fell by 49% (HR 0.51) and the risk of loss of life by 42% (HR 0.58). At two years, the proportion of patients alive without an event was 64% versus 45%, and the proportion alive was 78% versus 69%. The rate of no tumour remaining at surgery was 40% versus 8%.
How does it differ from pembrolizumab and enfortumab vedotin?
Both treatments are approved for patients who cannot receive cisplatin. In the durvalumab regimen, enfortumab vedotin is not given after surgery, only durvalumab continues, and the approval explicitly covers patients declining cisplatin as well. Because the two treatments have not been compared directly, it is not known which is more effective.
Can this treatment be used in Türkiye?
Durvalumab and enfortumab vedotin are licensed in Türkiye, but as of November 2026 this perioperative use is not included in the licence. Off-label approval from the Ministry of Health is required for its use, and SGK reimbursement is not expected.

Glossary

Muscle-invasive bladder cancer
The stage of bladder cancer in which the tumour has grown into the muscle layer of the bladder wall.
Radical cystectomy
Surgical removal of the bladder and the surrounding lymph nodes.
Perioperative treatment
Drug treatment given both before and after surgery.
Neoadjuvant / adjuvant
Treatment given before surgery / after surgery.
Cisplatin-ineligible
A patient who cannot receive cisplatin because of kidney function, hearing, nerve damage, the heart or general condition.
Antibody–drug conjugate
A treatment that carries a drug into the cell, attached to an antibody that recognises a tumour-specific protein.
Nectin-4
A protein found in abundance on the surface of bladder cancer cells and targeted by enfortumab vedotin.
PD-L1
A protein that tumour cells use to put the brakes on the immune system.
Event-free survival (EFS)
The time that passes without the disease progressing, coming back or an event that prevents surgery.
Pathological complete response
No viable tumour found under the microscope in the tissue removed at surgery.

DROZDOGAN Academy Commentary

For many years, patients with muscle-invasive bladder cancer who cannot receive cisplatin were among the groups with no option other than surgery and who benefited least from advances in cancer treatment. Two separate phase 3 trials showing a survival gain within a single year has changed this picture.

⚡ Why it matters

About half of bladder cancer patients cannot receive cisplatin. There are now two options that prolong survival for these patients, which makes it possible to personalise treatment according to the patient's risk of side effects and preferences.

✅ Strengths

Significant benefit in both event-free and overall survival; a fivefold increase in pathological complete response; no reduction in the surgery rate; no antibody–drug conjugate after surgery; inclusion of patients who decline chemotherapy.

⚠️ Limitations

Short follow-up (about 2 years); median survival times have not been reached. Open-label trial. Serious side effects more frequent than in the control arm. No direct comparison with the pembrolizumab combination. This use is off-licence in Türkiye.

🩺 In practice

In every patient diagnosed with muscle-invasive bladder cancer, I first assess eligibility for cisplatin. With my patients who cannot receive cisplatin, I discuss the options of immunotherapy and an antibody–drug conjugate before surgery, bladder-sparing treatment and the access conditions in our country, together with the urology and radiation oncology teams.

❓ Open questions

Which of the durvalumab and pembrolizumab combinations suits whom better? Can surgery be avoided in patients with a pathological complete response or ctDNA clearance? Can the length of post-operative treatment be shortened? What will the long-term results be?

Bottom line: Durvalumab and enfortumab vedotin has become the second perioperative option that prolongs survival in patients with muscle-invasive bladder cancer who cannot receive or do not want cisplatin. The choice should be made individually, taking into account the different side-effect profiles, treatment durations and access conditions of the two combinations.

Transparency note
  • This article was prepared in November 2026.
  • The approval information is based on the FDA announcement dated 13 November 2026; the VOLGA data are based on news reports of the ESMO 2026 presentation and on summaries published after the approval. VOLGA has not yet been published as a full paper.
  • The pathological complete response rate was reported as 40% versus 8% in the post-approval summaries and as 45% versus 10% in the congress abstracts; the article uses the former values. The difference may be due to the assessment method.
  • The comparison with the pembrolizumab combination is indirect. The scope of the Turkish licences for durvalumab and enfortumab vedotin could not be verified in detail at the time of writing.
  • The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make your health decisions together with your doctor.

References

  1. U.S. Food and Drug Administration. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer (13 November 2026).
  2. OncLive. FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC (November 2026). onclive.com
  3. OncoDaily. VOLGA at ESMO 2026: perioperative durvalumab with or without tremelimumab plus enfortumab vedotin in MIBC. oncodaily.com
  4. AstraZeneca. Perioperative IMFINZI plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in EFS and OS in MIBC in the Phase III VOLGA trial (2026). astrazeneca-us.com
  5. AJMC. FDA approves pembrolizumab plus enfortumab vedotin for MIBC (KEYNOTE-905, November 2025). ajmc.com
  6. Pharmacy Times. Pembrolizumab plus EV regimens receive FDA approval for muscle-invasive bladder cancer (KEYNOTE-B15, July 2026). pharmacytimes.com
  7. Oncology Nursing News. FDA approves perioperative durvalumab plus chemotherapy for MIBC (NIAGARA, March 2025). oncnursingnews.com
  8. Powles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (NIAGARA). N Engl J Med 2024;391:1773-1786. doi:10.1056/NEJMoa2408154. nejm.org
  9. İlacabak. Padcev 20 mg, Türkiye product information. ilacabak.com
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Pre-Post Surgery Options for Bladder Cancer: Durvalumab and Enfortumab Received FDA Approval

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy